Development of a Listeria monocytogenes based vaccine against prostate cancer

Cancer Immunology, Immunotherapy

Volumn 57, Issue 9, 2008, Pages 1301-1313

  Shahabi, Vafa ^a   Reyes Reyes, Mariela ^a   Wallecha, Anu ^a   Rivera, Sandra ^a   Paterson, Yvonne ^b   MacIag, Paulo ^a  

^a ADVAXIS INC   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer vaccine; Immunotherapeutic; Listeria monocytogenes; Listeriolysin O; PSA

Indexed keywords

BACTERIAL VACCINE; CANCER VACCINE; DNA VACCINE; EPITOPE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; LISTERIOLYSIN O PROSTATE SPECIFIC ANTIGEN FUSION PROTEIN; LISTERIOLYSIN O PROTEIN E7 FUSION PROTEIN; LIVE VACCINE; PROSTATE SPECIFIC ANTIGEN[65 74]; RECOMBINANT VACCINE; VACCINIA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER MODEL; CANCER REGRESSION; CARCINOMA CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; DRUG STABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; EXPRESSION VECTOR; GENE EXPRESSION; IMMUNOGENICITY; LISTERIA MONOCYTOGENES; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; REGULATORY T LYMPHOCYTE; SPLEEN CELL; STAINING;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; CANCER VACCINES; HEAT-SHOCK PROTEINS; HEMOLYSIN PROTEINS; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; LISTERIA MONOCYTOGENES; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; PROSTATIC NEOPLASMS; VIRULENCE;

EID: 45849139670     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-008-0463-z     Document Type: Article

References (46)

1. Jemal A et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57(1):43-66
2. Katz MH, McKiernan JM (2007) High-risk, clinically localized prostate cancer: is monotherapy adequate? Rev Urol 9(Suppl 2):S19-S27
3. Bhardwaj N (2007) Harnessing the immune system to treat cancer. J Clin Invest 117(5):1130-1136
4. Tricoli JV, Schoenfeldt M, Conley BA (2004) Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 10(12 Pt 1):3943-3953
5. Watt KW et al (1986) Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 83(10):3166-3170
6. Stamey TA et al (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317(15):909-916
7. Cunha AC et al (2006) Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett 236(2):229-238
8. Arlen PM et al (2006) A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12(4):1260-9
9. Heiser A et al (2002) Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109(3):409-417
10. Marshall DJ et al (2005) Induction of Th1-type immunity and tumor protection with a prostate-specific antigen DNA vaccine. Cancer Immunol Immunother 54(11):1082-1094
11. Noguchi M et al (2003) Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 57(1):80-92
12. Roos AK et al (2005) Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. Prostate 62(3):217-23
13. Gunn GR et al (2001) Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 167(11):6471-6479
14. Pan ZK et al (1995) Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine. Cancer Res 55(21):4776-4779
15. Singh R et al (2005) Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J Immunol 175(6):3663-3673
16. Pamer EG (2004) Immune responses to Listeria monocytogenes. Nat Rev Immunol 4(10):812-823
17. Foster BA et al (1997) Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57(16):3325-3330
18. Sambrook J, Russell D (2001) Molecular cloning: a laboratory manual (3-Volume Set) 3 Lab edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor
19. Peters C, Paterson Y (2003) Enhancing the immunogenicity of bioengineered Listeria monocytogenes by passaging through live animal hosts. Vaccine 21(11-12):1187-1194
20. Pavlenko M et al (2005) Identification of an immunodominant H-2D(b)-restricted CTL epitope of human PSA. Prostate 64(1):50-59
21. Blomberg K et al (1986) Europium-labelled target cells in an assay of natural killer cell activity. II. A novel non-radioactive method based on time-resolved fluorescence. significance and specificity of the method. J Immunol Methods 92(1):117-123
22. Decatur AL, Portnoy DA (2000) A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity. Science 290(5493):992-995
23. Lety MA et al (2001) Identification of a PEST-like motif in listeriolysin O required for phagosomal escape and for virulence in Listeria monocytogenes. Mol Microbiol 39(5):1124-1139
24. Schnupf P, Portnoy DA, Decatur AL (2006) Phosphorylation, ubiquitination and degradation of listeriolysin O in mammalian cells: role of the PEST-like sequence. Cell Microbiol 8(2):353-364
25. Leimeister-Wachter M et al (1990) Identification of a gene that positively regulates expression of listeriolysin, the major virulence factor of Listeria monocytogenes. Proc Natl Acad Sci USA 87(21):8336-8340
26. Stier EM, Mandal M, Lee KD (2005) Differential cytosolic delivery and presentation of antigen by listeriolysin O-liposomes to macrophages and dendritic cells. Mol Pharm 2(1):74-82
27. Bullock TN, Mullins DW, Engelhard VH (2003) Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells. J Immunol 170(4):1822-1829
28. Nitcheu-Tefit J et al (2007) Listeriolysin O expressed in a bacterial vaccine suppresses CD4+CD25high regulatory T cell function in vivo. J Immunol 179(3):1532-1541
29. Roos AK et al (2006) Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther 13(2):320-327
30. Tuteja R et al (2000) Augmentation of immune responses to hepatitis E virus ORF2 DNA vaccination by codelivery of cytokine genes. Viral Immunol 13(2):169-178
31. Hodge JW et al (1995) A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer 63(2):231-237
32. Lamikanra A et al (2001) Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site. J Virol 75(20):9654-9664
33. Lizee G et al (2006) Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res 12(16):4794-803
34. Yu P, Fu YX (2006) Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest 86(3):231-245
35. Hussain SF, Paterson Y (2004) CD4+CD25+ regulatory T cells that secrete TGFbeta and IL-10 are preferentially induced by a vaccine vector. J Immunother (1997) 27(5):339-346
36. Nishimura T et al (2000) The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 46(Suppl):S52-S61
37. Konig R et al (2002) The role of CD4 in regulating homeostasis of T helper cells. Immunol Res 25(2):115-130
38. Singh R, Paterson Y (2007) In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines. Cancer Immunol Immunother 56(6):927-38
39. Souders NC et al (2007) Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. Cancer Immun 7:2
40. Gulley J et al (2002) Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53(2):109-117
41. Pavlenko M et al (2004) A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 91(4):688-694
42. Schafer R et al (1992) Induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine. J Immunol 149(1):53-59
43. DiPaola RS et al (2006) A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med 4:1
44. Barrou B et al (2004) Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother 53(5):453-60
45. Su Z et al (2005) Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 174(6):3798-807
46. Rini BI et al (2006) Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 107(1):67-74